SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards

Background: Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis. Aims: To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance. Methods: Cross-sectional validation study in community-dwelling subject...

Descripción completa

Detalles Bibliográficos
Autores: Piotrowicz, Karolina, Gluszewska, Anna, Czesak, Joanna, Fedyk-Lukasik, Malgorzata, Klimek, Ewa, Sánchez-Rodríguez, Dolores, Skalska, Anna, Gryglewska, Barbara, Grodzicki, Tomasz, Gasowski, Jerzy
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/47134
Acceso en línea:http://hdl.handle.net/10230/47134
http://dx.doi.org/10.1007/s40520-020-01782-y
Access Level:acceso abierto
Palabra clave:DXA
EWGSOP2
SARC-F
Sarcopenia
Screening
id ES_f0e5fc0dd7e54e279d0e20bb07449f55
oai_identifier_str oai:repositori.upf.edu:10230/47134
network_acronym_str ES
network_name_str España
repository_id_str
spelling SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standardsPiotrowicz, KarolinaGluszewska, AnnaCzesak, JoannaFedyk-Lukasik, MalgorzataKlimek, EwaSánchez-Rodríguez, DoloresSkalska, AnnaGryglewska, BarbaraGrodzicki, TomaszGasowski, JerzyDXAEWGSOP2SARC-FSarcopeniaScreeningBackground: Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis. Aims: To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance. Methods: Cross-sectional validation study in community-dwelling subjects ≥ 65 years of age. Diagnosis of sarcopenia was based on the 2018 2nd European Working Group on Sarcopenia in Older People (EWGSOP2) consensus. Hand grip and 4-m gait speed were measured, and the Polish version of SARC-F was administered. Results: The mean (SD) age of 73 participants (21.9% men) was 77.8 (7.3) years. Seventeen participants (23.3%) fulfilled the EWGSOP2 criteria of sarcopenia, and 9 (12.3%) criteria for severe sarcopenia. Fourteen (19.2%) participants fulfilled the SARC-F criteria for clinical suspicion of sarcopenia. The Cronbach's alpha coefficient for internal was 0.84. With EWGSOP2 sarcopenia as a gold standard, the sensitivity of SARC-F was 35.3% (95% CI 14.2-61.7, p = 0.33), specificity was 85.7% (95% CI 73.8-93.6, p < 0.0001). The corresponding positive and negative predictive values were 42.9% (p = 0.79) and 81.4% (p < 0.0001), respectively. The probability of false-positive result was 14.3% (95% CI 6.4-26.2, p < 0.0001) and the probability of false-negative result was 64.7% (95% CI 38.3-85.8, p = 0.33). Overall the predictive power of SARC-F was low (c-statistic 0.64). Discussion: SARC-F is currently recommended for sarcopenia case finding in general population of older adults. However, its sensitivity is low, despite high specificity. Conclusions: At present SARC-F is better suited to rule out sarcopenia then to case-finding. Further refinement of screening for sarcopenia with the use of SARC-F seems needed.Springer202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/47134http://dx.doi.org/10.1007/s40520-020-01782-yreponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésAging Clin Exp Res. 2021;33(7):1821-9© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/471342026-06-12T07:21:37Z
dc.title.none.fl_str_mv SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
title SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
spellingShingle SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
Piotrowicz, Karolina
DXA
EWGSOP2
SARC-F
Sarcopenia
Screening
title_short SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
title_full SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
title_fullStr SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
title_full_unstemmed SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
title_sort SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards
dc.creator.none.fl_str_mv Piotrowicz, Karolina
Gluszewska, Anna
Czesak, Joanna
Fedyk-Lukasik, Malgorzata
Klimek, Ewa
Sánchez-Rodríguez, Dolores
Skalska, Anna
Gryglewska, Barbara
Grodzicki, Tomasz
Gasowski, Jerzy
author Piotrowicz, Karolina
author_facet Piotrowicz, Karolina
Gluszewska, Anna
Czesak, Joanna
Fedyk-Lukasik, Malgorzata
Klimek, Ewa
Sánchez-Rodríguez, Dolores
Skalska, Anna
Gryglewska, Barbara
Grodzicki, Tomasz
Gasowski, Jerzy
author_role author
author2 Gluszewska, Anna
Czesak, Joanna
Fedyk-Lukasik, Malgorzata
Klimek, Ewa
Sánchez-Rodríguez, Dolores
Skalska, Anna
Gryglewska, Barbara
Grodzicki, Tomasz
Gasowski, Jerzy
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv DXA
EWGSOP2
SARC-F
Sarcopenia
Screening
topic DXA
EWGSOP2
SARC-F
Sarcopenia
Screening
description Background: Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis. Aims: To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance. Methods: Cross-sectional validation study in community-dwelling subjects ≥ 65 years of age. Diagnosis of sarcopenia was based on the 2018 2nd European Working Group on Sarcopenia in Older People (EWGSOP2) consensus. Hand grip and 4-m gait speed were measured, and the Polish version of SARC-F was administered. Results: The mean (SD) age of 73 participants (21.9% men) was 77.8 (7.3) years. Seventeen participants (23.3%) fulfilled the EWGSOP2 criteria of sarcopenia, and 9 (12.3%) criteria for severe sarcopenia. Fourteen (19.2%) participants fulfilled the SARC-F criteria for clinical suspicion of sarcopenia. The Cronbach's alpha coefficient for internal was 0.84. With EWGSOP2 sarcopenia as a gold standard, the sensitivity of SARC-F was 35.3% (95% CI 14.2-61.7, p = 0.33), specificity was 85.7% (95% CI 73.8-93.6, p < 0.0001). The corresponding positive and negative predictive values were 42.9% (p = 0.79) and 81.4% (p < 0.0001), respectively. The probability of false-positive result was 14.3% (95% CI 6.4-26.2, p < 0.0001) and the probability of false-negative result was 64.7% (95% CI 38.3-85.8, p = 0.33). Overall the predictive power of SARC-F was low (c-statistic 0.64). Discussion: SARC-F is currently recommended for sarcopenia case finding in general population of older adults. However, its sensitivity is low, despite high specificity. Conclusions: At present SARC-F is better suited to rule out sarcopenia then to case-finding. Further refinement of screening for sarcopenia with the use of SARC-F seems needed.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/47134
http://dx.doi.org/10.1007/s40520-020-01782-y
url http://hdl.handle.net/10230/47134
http://dx.doi.org/10.1007/s40520-020-01782-y
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Aging Clin Exp Res. 2021;33(7):1821-9
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424051438485504
score 15,812429

Similares en LA Referencia